Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan

Chun Hui Lee, Tzu Chien Lin, Ming Yao, Liang Tsai Hsiao, Bor Sheng Ko, Chia Jen Liu, Tsai Yun Chen*


研究成果: Article同行評審


Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered for patients with high-risk B-cell lymphoma and relapsed or refractory disease. This study aimed to analyze the long-term follow-up data of patients who underwent allo-HSCT in Taiwan. This was a retrospective observational study using data from the Taiwan Society of Blood and Marrow Transplantation database. A total of 105 patients who underwent allo-HSCT because of high-risk, relapsed, or refractory disease between 2010 and 2019 were included. Forty-five percent of the patients previously underwent autologous stem cell transplantation (ASCT). The median follow-up duration was 18.6 months. The probability of 3-year progression-free survival and overall survival (OS) was 34.5% and 37%, respectively. The probability of 1-year non-relapse mortality was 31.4%, and the major cause was infection (75.8%). The multivariable analysis showed that not in remission at the time of transplantation and the absence of graft-versus-host disease (GVHD) were factors associated with inferior OS. The probability of 3-year OS in patients with diffuse large B-cell lymphoma who underwent allo-HSCT and allo-HSCT after ASCT was 40.2% and 25.2%, respectively. Allo-HSCT could be a salvage therapeutic option for relapsed or refractory B-cell lymphoma. Complete remission at the time of allo-HSCT and the presence of GVHD are independent variables for overall survival.

頁(從 - 到)21761-21769
期刊Cancer Medicine
出版狀態Published - 12月 2023


深入研究「Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan」主題。共同形成了獨特的指紋。